| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/CLPT.1990.94 |
| P698 | PubMed publication ID | 2357863 |
| P2093 | author name string | D M Roden | |
| A J Wood | |||
| H H Zhou | |||
| L B Anthony | |||
| P433 | issue | 6 | |
| P304 | page(s) | 686-693 | |
| P577 | publication date | 1990-06-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation | |
| P478 | volume | 47 |
| Q34122414 | Antiarrhythmic agents: drug interactions of clinical significance |
| Q35570981 | Antihypertensive therapy: special focus on drug interactions |
| Q41619585 | Clinical pharmacokinetic considerations in the elderly. An update |
| Q40712419 | Clinical significance of genetic influences on cardiovascular drug metabolism |
| Q28071256 | Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials |
| Q37268522 | Ethnic differences in drug disposition and responsiveness |
| Q43554154 | Food increases the bioavailability of tolterodine but not effective exposure |
| Q40832404 | Genetically determined adverse drug reactions involving metabolism |
| Q38773640 | Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs. |
| Q90700101 | Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma |
| Q73511084 | Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol |
| Q36923318 | Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications |
| Q51579932 | Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. |
| Q47404372 | Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects. |
| Q41598967 | Pharmacological importance of stereochemical resolution of enantiomeric drugs |
| Q37611786 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. |
| Q70493631 | Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol |
| Q40858967 | Stereoselective and isozyme-selective drug interactions |
| Q41940518 | Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias |
| Q71455359 | Stereoselective pharmacokinetics of [14C]-labeled KE-298, a new anti-rheumatic drug, in rats |
| Q77647233 | The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects |
| Q72113275 | The effect of zileuton on antipyrine and indocyanine green disposition* |
| Q41959654 | Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants |
| Q36851934 | Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions |
| Q40999769 | beta-blockers. Drug interactions of clinical significance |
Search more.